Today's Rundown UPDATE: Pfizer books Arena for immuno-inflammatory portfolio in $6.7B deal Hospitals across the country running out of beds, reducing surgeries amid latest COVID surge Special Report—The top 10 M&A targets in medtech for 2022 Novo Nordisk, underway with key launches, reveals $2.58B manufacturing investment Tidy up your labs, biotech. Pfizer is coming with 'significant firepower' and cash to burn From 340B to short-term health plans: Here are the top 4 regulations to watch for in 2022 ASH: Sanofi, Johnson & Johnson on collision course with Sarclisa, Darzalex 4-drug regimens in myeloma ASH: Novartis posts early clinical data on next-gen CAR-Ts, sets sights on 2022 registration trials Abbott elects CEO Ford chairman of the board as predecessor White retires after 40 years Bristol Myers Squibb, after massive Celgene takeover, plots $15B buyback plan Eli Lilly puts $1.3B in biobucks on the line for Foghorn's oncology programs How Morgan Health is making its accountable care pitch to providers FDA seeks input on regulating 3D-printed implants, devices made at the point of care Featured Story | By Annalee Armstrong Arena Pharmaceuticals has been in need of a new R&D show since a phase 2 pain drug flopped earlier this year, and, now, the biotech has landed the biggest ticket in town: Pfizer. The Big Pharma will add Arena to its bill in a deal valued at $6.7 billion, bringing on a suite of immuno-inflammatory disease candidates that target unmet needs. read more |
| |
|---|
|
|
| The PerkinElmer Biotech Bundle: advanced chemical and biologic data analytic software that represents complex data so key relationships can be better understood and decisions made with increased confidence. Learn more. |
Top Stories By Heather Landi One of Pennsylvania’s largest health systems is running at 110% capacity, with clinicians practicing “waiting room medicine” on patients who are forced to endure 10- to 20-hour delays in the emergency department. read more By Andrea Park,Conor Hale Even as 2021 looks to be a landmark year for medtech M&A, all signs point to 2022’s tally dwarfing this year's. M&A trends for 2022 will likely shake out into two broad categories: larger players looking for bolt-on deals and mid-size companies wanting to consolidate. And when it comes to who’s buying, the short answer is: everyone. read more By Kevin Dunleavy Novo Nordisk will invest $2.58 billion in expanding production capacity, building three new facilities and adding 400 jobs at its sprawling site in Kalundborg, Denmark. The expansion will help the company meet the growing demand for its diabetes treatments Ozempic and Rybelsus, plus obesity medicine Wegovy. read more By Annalee Armstrong Inquiring minds have wanted to know: what does Pfizer, loaded up with buckets of cash from the successful COVID-19 vaccine Comirnaty, want to buy? Executives gave a preview of what else they want on an investor call to discuss the $6.7 billion acquisition of Arena Pharmaceuticals this morning. read more By Robert King HHS released its unified agenda that details regulations it is planning for next year, including potential regulations for short-term plans and the 340B program. read more By Angus Liu Sanofi and Johnson & Johnson are adding more fuel to their CD38 rivalry fire between Sarclisa and Darzalex in multiple myeloma. With approvals already in place as triplet therapies, the two companies are now touting early clinical wins for four-drug regimens. read more By Nick Paul Taylor The next phase of Novartis’ CAR-T R&D strategy is well underway. With early clinical data on CD19 and BCMA-directed cell therapies in hand, the Big Pharma is preparing to move into registration trials next year. read more By Andrea Park As his second year at the helm of the medtech giant draws to a close, Abbott CEO Robert Ford is adding a new title to his résumé. read more By Fraiser Kansteiner Heading into 2022, large drugmakers are said to have more than $1.7 trillion in their M&A war chests. But after a huge buyout of its own, Bristol Myers Squibb is unveiling another use for its cash—and it's one that pharma often faces criticism for. read more By Kyle LaHucik Eli Lilly has inked a $380 million deal for access to multiple discovery-stage oncology programs from Foghorn Therapeutics. The co-development and co-commercialization agreement gives Lilly access to potential treatments targeting a mutation that is found in about 5% of all tumors. read more By Paige Minemyer Morgan Health, the new healthcare arm of JPMorgan Chase, wants to shift the paradigm for the employer health market to more accountable care. And now, it's making its pitch to providers on why they should be a part of that endeavor. read more By Conor Hale The FDA has begun outlining a potential approach for regulating a cutting-edge front emerging in healthcare: the 3D printing of medical implants or devices customized for each individual patient and manufactured on-site and on-demand within hospitals or doctor’s offices. read more |
